Lung Cancer News and Research

Latest Lung Cancer News and Research

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today highlighted a further analysis of the large randomized Phase II OPUS study demonstrating an association between early tumor shrinkage and long-term median overall survival (OS) of more than 2 years for patients with KRAS wild-type metastatic colorectal cancer (mCRC) treated with Erbitux® (cetuximab) plus FOLFOX standard chemotherapy.

19 Jan 2011

New study provides insight into developing therapeutics for airway disease

Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease.

19 Jan 2011

New data on role of miR-34 tumor suppressor in preventing cancer stem cell development

Mirna Therapeutics, Inc., a leading developer of microRNA (miRNA)-based therapeutics, announced today the publication of new data in the journal Nature Medicine describing the role of the tumor suppressor miRNA, miR-34, in preventing cancer stem cell development. The published results reveal that miR-34 is commonly down-regulated in prostate cancer stem cells and that this down-regulation is essential for cancer stem cell viability.

18 Jan 2011

Hamilton Academy of Medicine launches campaign to increase awareness about smoking cessation

In honour of National Non-Smoking Week, The Hamilton Academy of Medicine is proud to introduce, It's Hamilton's Time to Quit, a campaign designed to increase awareness about local quitting resources and tools to help the community understand the support that is available, and encourage people to seek the assistance they need to stop smoking.

18 Jan 2011

New way to halt lung inflammation

Acute inflammation of the lung is a poorly recognized human disease that develops in surprising and unexpected ways. The acute lung injury (ALI) or adult respiratory distress syndrome (ARDS) is a vital new concern for soldiers, but it can develop in anyone during a systemic infection, after severe trauma, as a result of bone fracture, following severe burns and in many other ways as well-- the initial cause may have nothing apparent to do with the lung itself.

18 Jan 2011

Smoking harms DNA within minutes: Study

According to the latest research in the US, smoking tobacco damages the body in minutes rather than years. The study was published in the Chemical Research in Toxicology revealed that the chemicals which cause cancer form rapidly after smoking.

16 Jan 2011

Scientists demonstrate mechanism that explains why PSA levels promote prostate cancer

Researchers at the Duke Cancer Institute who have been studying prostate cancer cells for decades now think they know why PSA levels reflect cancer progression.

14 Jan 2011

20% of cancer survivors experience chronic pain: Study

Surviving cancer may also mean surviving pain, according to a study by the University of Michigan Health System showing 20 percent of cancer survivors at least two years post diagnosis have current cancer-related chronic pain.

13 Jan 2011

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

The Biotechnology Industry Organization (BIO) today announced the selection of therapeutic workshops to be presented at the Thirteenth Annual BIO CEO & Investor Conference, taking place February 14-15.

13 Jan 2011

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) today announced that it has entered into a joint collaboration with Synta Pharmaceuticals for the clinical development of ganetespib (formerly STA-9090) in patients with multiple myeloma.

13 Jan 2011

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011.

13 Jan 2011

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.

12 Jan 2011

Salix and CCA offer Colonoscopy For Dummies

Salix Pharmaceuticals, Ltd., in partnership with the Colon Cancer Alliance (CCA), is proud to announce the availability of Colonoscopy For Dummies.

12 Jan 2011

Epigenetic therapy holds promise for cancer management

Syndax, a clinical-stage epigenetics oncology company, announced publication of data of entinostat combined with the demethylating agent Vidaza® (azacitidine) showing effect in reducing tumor burden in differentiated tumor cells in animal tumor models of non-small cell lung cancer (NSCLC). The data is being published in the January 15, 2011 issue of Cancer Research.

12 Jan 2011

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

Cyclacel Pharmaceuticals, Inc., today announced that it has opened enrollment of the SEAMLESS pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment of elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

11 Jan 2011

Study supports use of telomerase inhibitors for treatment of childhood cancers

Geron Corporation today announced the publication of preclinical data demonstrating that the company's telomerase inhibitor drug, imetelstat (GRN163L), currently in Phase 2 clinical trials, selectively targets cancer stem cells in pediatric tumors of neural origin.

11 Jan 2011

VCU Massey Cancer Center introduces safer, more effective form of radiation therapy

Virginia Commonwealth University Massey Cancer Center has introduced a safer and more effective form of radiation therapy to treat cancer. The Center now offers volumetric modulated arc therapy (VMAT) delivery using the Philips Pinnacle3 SmartArc software to provide radiation treatment for multiple tumor sites, including prostate, head and neck, brain, breast and lung. VCU Massey is the first cancer center in the Richmond area to offer this cutting-edge radiation technique.

10 Jan 2011

Neomend receives CE Mark for ProGEL PLATINUM Surgical Sealant

Neomend, Inc., an innovator in sealant and adhesion-prevention products for the surgical marketplace, announced it has received the European Union CE Mark for the company's ProGEL® PLATINUM Surgical Sealant.

10 Jan 2011

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Oncolytics Biotech Inc. announced today that a U.S. Phase I study of REOLYSIN® in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer (REO 022) is now open to enrollment. The principal investigator is Dr. Sanjay Goel of the Montefiore Medical Center at The Albert Einstein College of Medicine in New York.

10 Jan 2011

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.

10 Jan 2011

Lung Cancer News and Research

Latest Lung Cancer News and Research

New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux

New study provides insight into developing therapeutics for airway disease

New data on role of miR-34 tumor suppressor in preventing cancer stem cell development

Hamilton Academy of Medicine launches campaign to increase awareness about smoking cessation

New way to halt lung inflammation

Smoking harms DNA within minutes: Study

Scientists demonstrate mechanism that explains why PSA levels promote prostate cancer

20% of cancer survivors experience chronic pain: Study

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

Pfizer initiates rolling submission of crizotinib NDA for ALK-positive advanced NSCLC

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Salix and CCA offer Colonoscopy For Dummies

Epigenetic therapy holds promise for cancer management

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

Study supports use of telomerase inhibitors for treatment of childhood cancers

VCU Massey Cancer Center introduces safer, more effective form of radiation therapy

Neomend receives CE Mark for ProGEL PLATINUM Surgical Sealant

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

The ultimate guide to lung research tools and protocols eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in